Complications of Central Venous Access Devices in Patients With Sickle Cell Disease and Thalassemia Major.
Adolescent
Anemia, Sickle Cell
/ complications
Catheter-Related Infections
/ etiology
Catheterization, Central Venous
/ adverse effects
Central Venous Catheters
/ adverse effects
Child
Child, Preschool
Female
Humans
Infant
Male
Retrospective Studies
Thrombosis
/ etiology
beta-Thalassemia
/ complications
Journal
Journal of pediatric hematology/oncology
ISSN: 1536-3678
Titre abrégé: J Pediatr Hematol Oncol
Pays: United States
ID NLM: 9505928
Informations de publication
Date de publication:
01 07 2021
01 07 2021
Historique:
received:
14
05
2020
accepted:
15
09
2020
pubmed:
24
10
2020
medline:
11
9
2021
entrez:
23
10
2020
Statut:
ppublish
Résumé
Pediatric patients with sickle cell disease and thalassemia major present clinical characteristics that could lead to a higher incidence of central venous access devices-associated complications (CVAD-C). With the objective of analyzing the safety of the use of CVAD in these patients, a retrospective review including all pediatric patients with these pathologies who required the implantation of a CVAD between 2004 and 2019 was performed. In all, 54 patients with 100 CVAD (65 totally implantable venous access port with subcutaneous reservoir, 35 single-lumen or double-lumen partially tunneled catheter) were included. During 60,410 days at risk of suffering a CVAD-C, 55 complications (complication rate [CR]/1000 catheter-days at risk=0.91) were reported in 46 CVAD: 19 mechanicals (CR=0.32), 32 infectious (CR=0.53), and 4 thrombotic complications (CR=0.066). Incidence of mechanical and infectious complications was significantly higher in double-lumen partially tunneled catheter than in totally implantable venous access port with subcutaneous reservoir (P<0.001). Lower age at insertion was related with a higher incidence of any complication (odds ratio=0.88/y, P=0.02). Patients who required a stem cell transplantation (31 patients and 65 CVAD) had no significant higher incidences of CVAD-C. In conclusion, our study supports the safety of using CVAD in these patients, with a low incidence of infectious, thrombotic, and mechanical complications.
Identifiants
pubmed: 33093353
pii: 00043426-202107000-00019
doi: 10.1097/MPH.0000000000001972
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e655-e660Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: Summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312:1033–1048.
Cela De Julián E, Dulín Íñiguez E, Guerrero Soler M, et al. Evaluación en el tercer año de implantación del cribado neonatal universal de anemia falciforme en la Comunidad de Madrid [Evaluation of systematic neonatal screening for sickle cell diseases in Madrid three years after its introduction]. An Pediatr. 2007;66:382–386.
Carraro F, Cicalese MP, Cesaro S, et al. Guidelines for the use of long-term central venous catheter in children with hemato-oncological disorders. on behalf of supportive therapy working group of Italian Association of Pediatric Hematology and Oncology (AIEOP). Ann Hematol. 2013;92:1405–1412.
Rincón-López EM, Navarro Gómez ML, Hernández-Sampelayo Matos T, et al. Low-risk factors for severe bacterial infection and acute chest syndrome in children with sickle cell disease. Pediatr Blood Cancer. 2019;66:e27667.
Booth C, Inusa B, Obaro SK. Infection in sickle cell disease: a review. Int J Infect Dis. 2010;14:2–12.
Ellison AM, Ota KV, McGowan KL, et al. Epidemiology of bloodstream infections in children with sickle cell disease. Pediatr Infect Dis J. 2013;32:560–563.
Faes C, Sparkenbaugh EM, Pawlinski R. Hypercoagulable state in sickle cell disease. Clin Hemorheol Microcirc. 2018;68:301–318.
Sparkenbaugh E, Pawlinski R. Prothrombotic aspects of sickle cell disease. J Thromb Haemost. 2017;15:1307–1316.
Abdul-Rauf A, Gauderer M, Chiarucci K, et al. Long-term central venous access in patients with sickle cell disease. J Pediatr Hematol Oncol. 1995;17:342–345.
Raj A, Bertolone S, Bond S, et al. Cathlink® 20: a subcutaneous implanted central venous access device used in children with sickle cell disease on long-term erythrocytapheresis-a report of low complication rates. Pediatr Blood Cancer. 2005;44:669–672.
Shah R, Thornburg CD, Rothman J, et al. Complications of implantable venous access devices in patients with sickle cell disease. Am J Hematol. 2011;87:224–226.
Jeng MR, Feusner J, Skibola C, et al. Central venous catheter complications in sickle cell disease. Am J Hematol. 2002;69:103–108.
Wagner SC, Eschelman DJ, Gonsalves CF, et al. Infectious complications of implantable venous access devices in patients with sickle cell disease. J Vasc Interv Radiol. 2004;15:375–378.
Alkindi S, Matwani S, Al-Maawali A, et al. Complications of PORT-A-CATH ® in patients with sickle cell disease. J Infect Public Health. 2012;5:57–62.
Vermylen C, Cornu G, Ferster A, et al. Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplant. 1998;22:1–6.
Walters MC, Storb R, Patience M, et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Blood. 2000;95:1918–1924.
Panepinto JA, Walters MC, Carreras J, et al. Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research. Br J Haematol. 2007;137:479–485.
Bernaudin F, Socie G, Kuentz M, et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood. 2019;110:2749–2757.
SEHOP 2019. Sickle Cell Disease. Clinical Practice Guidelines. 1st ed (Spanish). 2019. Available at: http://www.sehop.org/wp-content/uploads/2019/03/Gu%C3%ADa-SEHOP-Falciforme-2019.pdf .
Tubman VN, Fung EB, Vogiatzi M, et al. Guidelines for the standard monitoring of patients with thalassemia: report of the thalassemia longitudinal cohort. J Pediatr Hematol Oncol. 2015;37:e162–e169.
Jamshidi R. Central venous catheters: Indications, techniques, and complications. Semin Pediatr Surg. 2019;28:26–32.
Mermel L a, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49:1–45.
Rosenbluth G, Tsang L, Vittinghoff E, et al. Impact of decreased heparin dose for flush-lock of implanted venous access ports in pediatric oncology patients. Pediatr Blood Cancer. 2014;61:855–858.
Lee ACW, Ong ND. Can implanted venous access ports remain patent without maintenance flush-lock? Pediatr Blood Cancer. 2014;61:2326–2326.
Cesaro S, Cavaliere M, Pegoraro A, et al. A comprehensive approach to the prevention of central venous catheter complications: results of 10-year prospective surveillance in pediatric hematology-oncology patients. Ann Hematol. 2016;95:817–825.
Fratino G, Molinari AC, Parodi S, et al. Central venous catheter-related complications in children with oncological/hematological diseases: an observational study of 418 devices. Ann Oncol. 2005;16:648–654.
van den Bosch CH, van der Bruggen JT, Frakking FNJ, et al. Incidence, severity and outcome of central line related complications in pediatric oncology patients: a single center study. J Pediatr Surg. 2019;54:1894–1900.
Adler A, Yaniv I, Solter E, et al. Catheter-associated bloodstream infections in pediatric hematology-oncology patients. factors associated with catheter removal and recurrence. J Pediatr Hematol Oncol. 2006;28:23–28.
Yeral M, Boga C, Oguzkurt L, et al. Short-term central venous catheter complications in patients with sickle cell disease who undergo apheresis. J Thromb Thrombolysis. 2014;37:97–101.
Pinon M, Bezzio S, Tovo PA, et al. A prospective 7-year survey on central venous catheter-related complications at a single pediatric hospital. Eur J Pediatr. 2009;168:1505–1512.
Al-Maskari B, Al-Maawali A, Matwani S, et al. Complications of PORT-A-CATH® in patients with sickle cell disease. J Infect Public Health. 2011;5:57–62.